CU23077A1 - Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas - Google Patents

Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Info

Publication number
CU23077A1
CU23077A1 CU20000286A CU20000286A CU23077A1 CU 23077 A1 CU23077 A1 CU 23077A1 CU 20000286 A CU20000286 A CU 20000286A CU 20000286 A CU20000286 A CU 20000286A CU 23077 A1 CU23077 A1 CU 23077A1
Authority
CU
Cuba
Prior art keywords
malignal
alfa
tgf
growth factor
composition containing
Prior art date
Application number
CU20000286A
Other languages
English (en)
Inventor
Sierra Aillette Mulet
Rodriguez Rolando Perez
Marinello Gisela Maria Gonzalez
Acosta Anabel Alvarez
Medina Tamara Menendez
Nieto Gerardo Enrique Guillen
Ramirez Belinda Sanchez
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Priority to CU20000286A priority Critical patent/CU23077A1/es
Priority to PE2001001201A priority patent/PE20020696A1/es
Priority to ARP010105663A priority patent/AR031785A1/es
Priority to MYPI20015557A priority patent/MY141122A/en
Priority to JP2002547521A priority patent/JP2004521091A/ja
Priority to CNA2008100876617A priority patent/CN101406692A/zh
Priority to UY27060A priority patent/UY27060A1/es
Priority to BR0116017-6A priority patent/BR0116017A/pt
Priority to US10/003,462 priority patent/US20030054011A1/en
Priority to PCT/CU2001/000011 priority patent/WO2002045738A2/es
Priority to AU2002221520A priority patent/AU2002221520B2/en
Priority to EA200300638A priority patent/EA006240B1/ru
Priority to KR1020037007631A priority patent/KR100834383B1/ko
Priority to AT01999383T priority patent/ATE439855T1/de
Priority to DE60139633T priority patent/DE60139633D1/de
Priority to NZ526283A priority patent/NZ526283A/en
Priority to MXPA03005031A priority patent/MXPA03005031A/es
Priority to EP01999383A priority patent/EP1339425B1/en
Priority to CA002430621A priority patent/CA2430621A1/en
Priority to AU2152002A priority patent/AU2152002A/xx
Priority to CNA018214347A priority patent/CN1482916A/zh
Priority to ES01999383T priority patent/ES2332125T3/es
Priority to ZA200304416A priority patent/ZA200304416B/en
Publication of CU23077A1 publication Critical patent/CU23077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
CU20000286A 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas CU23077A1 (es)

Priority Applications (23)

Application Number Priority Date Filing Date Title
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
PE2001001201A PE20020696A1 (es) 2000-12-06 2001-11-29 Composicion vacunal que contiene factor de crecimiento transformante (tgfo)
ARP010105663A AR031785A1 (es) 2000-12-06 2001-12-05 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
MYPI20015557A MY141122A (en) 2000-12-06 2001-12-05 Vaccine composition containing transforming growth factor alpha (tgf[alpha]). it use in malignant diseases therapy
JP2002547521A JP2004521091A (ja) 2000-12-06 2001-12-06 トランスフォーミング増殖因子アルファを含有するワクチン組成物
CNA2008100876617A CN101406692A (zh) 2000-12-06 2001-12-06 含有转化生长因子α的疫苗组合物
UY27060A UY27060A1 (es) 2000-12-06 2001-12-06 Composición vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
BR0116017-6A BR0116017A (pt) 2000-12-06 2001-12-06 Composição de vacina capaz de produzir uma resposta imune especìfica contra o tgf-alfa autólogo
US10/003,462 US20030054011A1 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha (TGFalpha). it use in malignant diseases therapy
PCT/CU2001/000011 WO2002045738A2 (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa
AU2002221520A AU2002221520B2 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
EA200300638A EA006240B1 (ru) 2000-12-06 2001-12-06 Вакцинная композиция, содержащая трансформирующий фактор роста альфа
KR1020037007631A KR100834383B1 (ko) 2000-12-06 2001-12-06 전환 성장 인자 알파를 함유하는 백신 조성물
AT01999383T ATE439855T1 (de) 2000-12-06 2001-12-06 Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
DE60139633T DE60139633D1 (de) 2000-12-06 2001-12-06 Transformierender wachstumsfaktor alpha enthaltende impfstoffzusammensetzung
NZ526283A NZ526283A (en) 2000-12-06 2001-12-06 Vaccine composition containing human transforming growth factor alpha fused to a carrier protein and optionally contain an EGF-R ligand
MXPA03005031A MXPA03005031A (es) 2000-12-06 2001-12-06 Composicion vacunal que contiene factor de crecimiento transformante alfa.
EP01999383A EP1339425B1 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
CA002430621A CA2430621A1 (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
AU2152002A AU2152002A (en) 2000-12-06 2001-12-06 Vaccine composition containing transforming growth factor alpha
CNA018214347A CN1482916A (zh) 2000-12-06 2001-12-06 含有转化生长因子α的疫苗组合物
ES01999383T ES2332125T3 (es) 2000-12-06 2001-12-06 Composicion de vacuna que contiene el factor de crecimiento transformante alfa.
ZA200304416A ZA200304416B (en) 2000-12-06 2003-06-05 Vaccine composition containing transforming growth factor alpha.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Publications (1)

Publication Number Publication Date
CU23077A1 true CU23077A1 (es) 2005-08-17

Family

ID=34109588

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20000286A CU23077A1 (es) 2000-12-06 2000-12-06 Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas

Country Status (21)

Country Link
US (1) US20030054011A1 (es)
EP (1) EP1339425B1 (es)
JP (1) JP2004521091A (es)
KR (1) KR100834383B1 (es)
CN (2) CN1482916A (es)
AR (1) AR031785A1 (es)
AT (1) ATE439855T1 (es)
AU (2) AU2152002A (es)
BR (1) BR0116017A (es)
CA (1) CA2430621A1 (es)
CU (1) CU23077A1 (es)
DE (1) DE60139633D1 (es)
EA (1) EA006240B1 (es)
ES (1) ES2332125T3 (es)
MX (1) MXPA03005031A (es)
MY (1) MY141122A (es)
NZ (1) NZ526283A (es)
PE (1) PE20020696A1 (es)
UY (1) UY27060A1 (es)
WO (1) WO2002045738A2 (es)
ZA (1) ZA200304416B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU23204A1 (es) * 2002-12-27 2007-05-18 Ct Ingenieria Genetica Biotech Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
KR101323845B1 (ko) 2011-01-21 2013-10-31 광주과학기술원 외막소포체를 유효성분으로 포함하는 항암용 약제학적 조성물
CN113855792B (zh) * 2021-12-01 2022-03-01 上海惠盾因泰生物科技有限公司 重组hEGF-CRM197肿瘤治疗性疫苗配制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2063271A1 (en) * 1989-07-14 1991-01-15 Subramonia Pillai Cytokine and hormone carriers for conjugate vaccines
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
CA2261433A1 (en) 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals

Also Published As

Publication number Publication date
WO2002045738A3 (es) 2003-02-20
AU2152002A (en) 2002-06-18
CN101406692A (zh) 2009-04-15
NZ526283A (en) 2004-11-26
CN1482916A (zh) 2004-03-17
ES2332125T3 (es) 2010-01-27
EA200300638A1 (ru) 2003-10-30
DE60139633D1 (de) 2009-10-01
AU2002221520B2 (en) 2007-10-11
US20030054011A1 (en) 2003-03-20
KR100834383B1 (ko) 2008-06-09
BR0116017A (pt) 2004-01-13
KR20030061424A (ko) 2003-07-18
PE20020696A1 (es) 2002-09-19
AR031785A1 (es) 2003-10-01
WO2002045738A2 (es) 2002-06-13
CA2430621A1 (en) 2002-06-13
ZA200304416B (en) 2004-07-07
EA006240B1 (ru) 2005-10-27
ATE439855T1 (de) 2009-09-15
JP2004521091A (ja) 2004-07-15
EP1339425B1 (en) 2009-08-19
EP1339425A2 (en) 2003-09-03
UY27060A1 (es) 2002-03-22
MXPA03005031A (es) 2004-09-10
MY141122A (en) 2010-03-15

Similar Documents

Publication Publication Date Title
ATA1292000A (de) Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
DE60127002D1 (de) Pharmazeutische zusammensetzung
NO20023674D0 (no) Regulerbar stol
DE60044269D1 (de) Krankenliege
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
AR027976A1 (es) Anticuerpos humanos para cd154
NO996133D0 (no) Olje-i-vann-vaksinesammensetninger
IS6779A (is) Mannlíkt mótefni gegn LT-beta-R
ATE490327T1 (de) Impfstoffzusammensetzung
NO20031483L (no) Vaksine
NO20024172L (no) Vaksine
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
BR0010418B1 (pt) microorganismo de salmonella, composiÇço de vacina e uso do referido microorganismo.
UY26297A1 (es) Vacuna
DZ2283A1 (fr) Composition de vaccin.
FI20000818A0 (fi) Dermatologinen käyttö ja valmiste
DE60129238D1 (de) Pharmazeutische zusammensetzung
CU23077A1 (es) Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
AR027954A1 (es) Encendedor de uso general
NO20023517D0 (no) Stol
NO20003763L (no) Regulerbar stol
IT1317850B1 (it) Strumento per la pulizia, in particolare ad uso medicale.
AU2001291202A1 (en) Avian pneumovirus vaccine
IT1316942B1 (it) Preparato per uso esterno.
BR0104878B1 (pt) vaporizador direcional de uso humano.